2021
DOI: 10.1182/blood-2021-145111
|View full text |Cite
|
Sign up to set email alerts
|

Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial

Abstract: Introduction: Approximately 30-35% of patients with classic Hodgkin Lymphoma will prove refractory to frontline therapy or relapse subsequently. Traditional second-line chemotherapy regimens including ifosfamide, carboplatin, and etoposide (ICE) result in complete response rates of ~50%. Achievement of complete metabolic response (CMR) assessed by PET/CT imaging prior to autologous hematopoietic stem cell transplant (AHSCT) predicts favorable progression free survival (PFS) and overall survival (OS). PD-1 bloc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
20
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 18 publications
(20 citation statements)
references
References 0 publications
0
20
0
Order By: Relevance
“…16,18,[24][25][26][27] However, the comparative efficacy of CPI-based salvage regimens versus conventional chemotherapy and BV-based regimens has not yet been previously established in a clinical trial or in a real-world cohort. [16][17][18][19] Our study is the largest multicenter real-world experience to evaluate the efficacy of novel CPI-based regimens compared to conventional chemotherapy and BV-based regimens in R/R cHL. Our data suggest that the impact of CPI-based regimens before ASCT may be substantial with significant improvements in EFS and PFS compared to other salvage regimens.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…16,18,[24][25][26][27] However, the comparative efficacy of CPI-based salvage regimens versus conventional chemotherapy and BV-based regimens has not yet been previously established in a clinical trial or in a real-world cohort. [16][17][18][19] Our study is the largest multicenter real-world experience to evaluate the efficacy of novel CPI-based regimens compared to conventional chemotherapy and BV-based regimens in R/R cHL. Our data suggest that the impact of CPI-based regimens before ASCT may be substantial with significant improvements in EFS and PFS compared to other salvage regimens.…”
Section: Discussionmentioning
confidence: 99%
“…15 In two independent single arm phase 2 trials, pembrolizumab leads to response rates of about 97.3 and 100% in combination with platinum-based and gemcitabine-based chemotherapy, respectively, with 24-month progression-free survival (PFS) of 88% and 100%, respectively. 16,17 In a single-arm phase 2 trial of 91 patients with recurrent cHL, salvage BV plus nivolumab leads to CR rate of 67% and 2 year PFS of 91%. 18 In an ongoing phase 2 study of 39 patients, the efficacy of sequential treatment with Nivolumab followed by ICE was studied.…”
Section: Introductionmentioning
confidence: 99%
“…Preliminary results of pembro with ICE were presented at the American Society of Hematology (ASH) meeting in 2021: 42 patients were enrolled, and 37 patients were evaluable for efficacy, for whom the CR rate was 86.5% and the 24-month PFS was 88.2%. Notably, one patient died of cardiac arrest during stem cell collection, and another patient succumbed to acute respiratory failure early post-autoHCT, attributed to engraftment syndrome [ 19 ].…”
Section: What Is the Optimal Second-line Therapy?mentioning
confidence: 99%
“…Given the strong clinical activity of these agents, there has been ongoing interest in exploring their role in the second-line setting and especially in the context of autoHCT, either as pre-autoHCT salvage, post-autoHCT consolidation, or both. While 2L treatment has historically consisted of cytotoxic chemotherapy, BV monotherapy [ 13 ], BV with concurrent chemotherapy [ 14 , 15 ], BV with nivo [ 16 ], nivo monotherapy [ 17 ], and nivo/pembro + chemotherapy [ 17 , 18 , 19 ] have all been tested as 2L treatments and used successfully to bridge patients to curative intent autoHCT. In fact, the long-standing dogma that chemosensitivity is an absolute requirement prior to autoHCT has been challenged given the success of CPI-based salvage followed by autoHCT, even in previously chemorefractory patients [ 20 ].…”
Section: Introductionmentioning
confidence: 99%
“…Other small studies evaluating combination of immunotherapy with standard regimens as bridge to ASCT, including pembrolizumab combined with ICE or gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), showed similarly high CR rates of 86–95% [ 36 ]. The active investigation of other anti-PD-1 mAb combination regimens via a PET-adapted approach using anti-PD1 mAb with GVD are underway to assess efficacy with less toxic or chemotherapy-sparing therapies ( Table 2 ).…”
Section: Immunotherapy As First Salvage and Bridge To Asctmentioning
confidence: 99%